AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7485045
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) with Lovastatin
Trial: 7011597
Drug: Intravenous LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous LHRH (100 micrograms)
Trial: 18193496
Drug: missing at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: missing at least 1 medication dose ever
Trial: 18193496
Drug: missing at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: missing at least 1 medication dose in the past month
Trial: 18193496
Drug: missing at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: missing at least 1 medication dose in the past weekend
Trial: 15134179
Drug: Long ZDV
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long ZDV treatment duration for mothers (more than 7.5 weeks)
Trial: 15134179
Drug: Short ZDV
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short ZDV treatment duration for mothers (no more than 7.5 weeks)
Trial: 15134179
Drug: Long ZDV
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received short treatment
Trial: 15134179
Drug: Short ZDV
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short ZDV treatment duration for infants (3 days) when mothers received short treatment
Trial: 15134179
Drug: Long ZDV
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received long treatment
Trial: 11402637
Drug: Heat plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat plus patch (5 mg androgen patch with heat-generating patch)
Trial: 11402637
Drug: Patch only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch only (5 mg androgen patch without heat)
Trial: 11402637
Drug: No patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No patch (no testosterone patch)
Trial: 3907331
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg bid
Trial: 3907331
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg hs
Trial: 3907331
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg hs
Trial: 3907331
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg bid
Trial: 3907331
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg hs
Trial: 10929897
Drug: IgA antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgA antibodies
Trial: 4202264
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies
Trial: 29627147
Drug: Neutralising antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralising antibodies
Trial: 31600715
Drug: Tourniquet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tourniquet plus intravenous tranexamic acid
Trial: 19811918
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + oral cyclophosphamide (RT+C)
Trial: 11123828
Drug: Penicillin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (two or more doses)
Trial: 11123828
Drug: Penicillin (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (one or fewer doses)
Trial: 11123828
Drug: Penicillin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (two doses)
Trial: 11123828
Drug: Penicillin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (three doses)
Trial: 8761138
Drug: 20 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g/d of PEG 4000 without electrolyte addition
Trial: 2862081
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg prostaglandin E2 (PGE2)
Trial: 2862081
Drug: gel only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel only
Trial: 24706842
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) for 6 months
Trial: 29025631
Drug: No isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No isoniazid preventive therapy (no IPT)
Trial: 12369756
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of glimepiride (1.0 mg)
Trial: 3479527
Drug: Oxiracetam 800
RxNorm normalized name: oxiracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam 800 mg bid
Trial: 25480348
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate 2 g/day plus alfacalcidol 1 μg
Trial: 22546009
Drug: Other artemisinin-based
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other artemisinin-based combination therapies (ACT)
Trial: 22546009
Drug: Both G6PD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both G6PD deficiency and CDA treatment
Trial: 20722560
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of dialysis treatments
Trial: 18222001
Drug: Conservative ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative ocular therapies and chemothermotherapy (intravenous carboplatin followed by transpupillary thermotherapy) after chemoreduction by 2 cycles of carboplatin and etoposide
Trial: 18222001
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (2 cycles of carboplatin and etoposide) followed by ocular therapy and chemothermotherapy
Trial: 18222001
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with ocular therapy and chemothermotherapy
Trial: 16152837
Drug: Pifubing Xuedu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pifubing Xuedu Pill (PXDP) combined with Diyin Tablet (DYT)
Trial: 12577369
Drug: Diyin Tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diyin Tablet (DYT) alone
Trial: 12063530
Drug: Injected heparin
RxNorm normalized name: heparin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected heparin
Trial: 11928567
Drug: Inhaled heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled heparin
Trial: 9987495
Drug: Regional chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional chemotherapy (historical control trials)
Trial: 7838635
Drug: Large volume
RxNorm normalized name: NEBULIZER,LARGE VOLUME #1770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large volume feeding (10 mL/kg)
Trial: 1978770
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg/d
Trial: 3105558
Drug: Astemizole 10
RxNorm normalized name: astemizole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 10 mg/d
Trial: 639831
Drug: Norethindrone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone (5 to 20 mg single oral doses)
Trial: 2561379
Drug: Intramuscular ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ACTH
Trial: 28829884
Drug: Oral Prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Prednisolone
Trial: 23281706
Drug: Melatonin 0.3
RxNorm normalized name: melatonin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 0.3 mg·kg(‐1)
Trial: 23281706
Drug: Clonidine 4
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 4 μg·kg(‐1)
Trial: 22332395
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon 2 in the form of suppositories (genferon and viferon)
Trial: 9695162
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pseudoephedrine
Trial: 8385564
Drug: Amonafide (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amonafide (1600 mg/m2, 24-hour continuous infusion every 21 days)
Trial: 8385564
Drug: Trimetrexate (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetrexate (150 mg/m2, intravenous over 30 minutes every 2 weeks)
Trial: 3083793
Drug: Prostacyclin infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin infusion, 50 ng per kilogram of body weight per minute during cardiopulmonary bypass (CPB)
Trial: 29626232
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g WP
Trial: 29626232
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g WP
Trial: 29626232
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g WP (placebo)
Trial: 25173357
Drug: Renal scan
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal scan at 12 months (Antibiotic group)
Trial: 19236691
Drug: 10 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 week programme of supervised aerobic exercises (twice weekly) and individually tailored brief intervention lifestyle counselling
Trial: 15147122
Drug: GM-CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (300 microg) + recombinant hepatitis B vaccine (40 microg)
Trial: 15147122
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: recombinant hepatitis B vaccine (40 microg)
Trial: 9053413
Drug: Herbal eye
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal eye drop preparation
Trial: 2874047
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with ipratropium bromide (two inhalations four times daily, 20 micrograms per inhalation) in combination with oral terbutaline and aerosolized salbutamol
Trial: 2874047
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide treatment
Trial: 28911067
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus bevacizumab (CAP-B) maintenance treatment
Trial: 16756416
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN) 0 mg
Trial: 16756416
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN) 7 mg
Trial: 18489014
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN) 14 mg
Trial: 16756416
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN) 21 mg
Trial: 15007373
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN)
Trial: 9362437
Drug: Pamidronate (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (120 mg, 2-hour infusion)
Trial: 1328567
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg once a day) for 8 days
Trial: 1328567
Drug: Hydralazine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (5 mg/day) and Captopril (25 mg/day) for 6 weeks
Trial: 1328567
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg once a day) and Nitrendipine (20 mg once a day)
Trial: 3900591
Drug: Melphalan plus
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan plus Prednisone (M.P.) X 6 monthly cycles
Trial: 3900591
Drug: Vincristine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine plus Melphalan plus Cyclophosphamide plus Prednisone (VMCP) X 6 monthly cycles
Trial: 29169840
Drug: Alfaxalone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (2 mg kg−1) with fentanyl (2 μg kg−1) for induction and alfaxalone variable rate infusion (VRI) combined with fentanyl constant rate infusion (CRI) (10 μg kg−1 hour−1) for maintenance (group AF)
Trial: 29169840
Drug: Alfaxalone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (2 mg kg−1) for induction and alfaxalone variable rate infusion (VRI) (0.15 mg kg−1 minute−1) for maintenance (group AP)
Trial: 24063556
Drug: Treatment-As-Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-As-Usual
Trial: 19587126
Drug: Low-fat, high-fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-fruit and -vegetable diets (mean intake: 6.1 servings/d of fruits and vegetables, 2.7 mg/d of lutein and zeaxanthin)
Trial: 19587126
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (standard diet, mean intake: 4.6 servings/d of fruits and vegetables, 2.1 mg/d of lutein and zeaxanthin)
Trial: 19587126
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of lutein and zeaxanthin (highest quintile, median 6.4 mg/d)
Trial: 11889149
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene (RLX) 60 mg/d
Trial: 11589267
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene (RLX) 120 mg/d
Trial: 11589267
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene (RLX) 60 mg/d in women with BMI >26.4 kg/m2
Trial: 11589267
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene (RLX) 120 mg/d in women with BMI >26.4 kg/m2
Trial: 9846035
Drug: Ondansetron (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (chronic treatment)
Trial: 9846035
Drug: Placebo (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (acute treatment)
Trial: 9846035
Drug: Placebo (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (chronic treatment)
Trial: 9337187
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of bupivacaine (TEA, Th1 to Th5)
Trial: 9337187
Drug: Standard anti‐anginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anti‐anginal therapy (control group)
Trial: 7945741
Drug: Biperiden, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden, 4 mg
Trial: 7945741
Drug: Bornaprine, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bornaprine, 4 mg
Trial: 2979234
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg kg‐1 h‐1 ranitidine
Trial: 2979234
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg kg‐1 h‐1 ranitidine
Trial: 19380382
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (6 mg)
Trial: 28960312
Drug: Immediate-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release niacin (2 g) with high-fat meals containing saturated fatty acids (SFAs)
Trial: 28960312
Drug: Immediate-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release niacin (2 g) with high-fat meals containing monounsaturated fatty acids (MUFAs)
Trial: 28960312
Drug: Immediate-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release niacin (2 g) with high-fat meals containing MUFAs plus omega-3 long-chain polyunsaturated fatty acids (LCPUFAs)
Trial: 28960312
Drug: Immediate-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release niacin (2 g) with high-fat meals containing no fat
Trial: 28386699
Drug: LSD (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (100 mcg orally)
Trial: 26175218
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1-3 ml) used for sealing the needle track (Group B)
Trial: 12544181
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg methylphenidate
Trial: 13680085
Drug: 0.30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/kg methylphenidate
Trial: 12544181
Drug: 0.60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.60 mg/kg methylphenidate
Trial: 9187188
Drug: Flow triggering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow triggering of 5/2 L/min
Trial: 9187188
Drug: Flow triggering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow triggering of 10/3 L/min
Trial: 8068446
Drug: Clodronate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (300 mg/daily for 5 days)
Trial: 8068446
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg/daily for 5 days) after clodronate in 7 relapsing patients
Trial: 8068446
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg/daily for 5 days) in 8 newly diagnosed patients
Trial: 3195851
Drug: CDP-choline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline (100 mg/kg/day for seven days)
Trial: 8836
Drug: Benorylate suspension
RxNorm normalized name: benorilate Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benorylate suspension for 7 days
Trial: 31186120
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (14 mg, once daily)
Trial: 31186120
Drug: Subcutaneous liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous liraglutide (1.8 mg, once daily)
Trial: 28513068
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for 12 weeks
Trial: 28513068
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for 12 weeks
Trial: 19480610
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine medicated plaster and pregabalin combination therapy
Trial: 19480610
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine medicated plaster monotherapy
Trial: 19480610
Drug: Pregabalin monotherapy
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin monotherapy
Trial: 19480610
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine medicated plaster with continued pregabalin treatment
Trial: 7726317
Drug: Fluphenazine 10
RxNorm normalized name: fluphenazine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine 10 mg/day
Trial: 7726317
Drug: Fluphenazine 20
RxNorm normalized name: fluphenazine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine 20 mg/day
Trial: 7726317
Drug: Fluphenazine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine 30 mg/day
Trial: 7726317
Drug: Fluphenazine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine (all doses)
Trial: 7262795
Drug: Daily interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interval therapy (alternating application of Jellin ointment or cream and their bases, n = 26)